Pds Biotechnology Corporation

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Pds Biotechnology Corporalion

Mkrtichyan, Mikayel

Khleif, Samir N.

Frank Bedu-Addo

Kenya Johnson

Leaf Huang

Eric Jacobson

Gregory Conn

Samir N Khleif

Mikayel Mkrtichyan

Jerold Woodward

Greg Conn

Martin Ward

Elizabeth Ann Vasievich

Kenya N Toney Johnson

Weihsu Claire Chen

Weihsu Chen

Siva K Gandhapudi

Weili Yan

Kenya Toney

Carol Mercer

The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of argumenting an immune response in a mammal, and methods of treating a diseases in a mammal utilizing the vaccine compositions.

Methods of modulating immune responses with cationic lipid vaccine compositions

The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.

Stimulation of an immune response by cationic lipids

The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.

Vaccine compositions and methods of use

A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in Ris a quaternary ammonium group, Yis a space chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, Rand Rare independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combination thereof.

Stimulation of an immune response by enantiomers of cationic lipids

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

Novel human papillomovirus immunogenic compositions and methods of use thereof are provided. The compositions comprise unique combinations of multi-epitope peptide sequences specifically selected and designed to be effectively processed and cross-presented to T-cells. The peptides utilized in the compositions display high levels of binding with HLA-supertypes. The immunogenic compositions are broadly applicable to large proportions of target populations. The compositions comprise adjuvants such as cationic lipids.

HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereof

Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositions

A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in Ris a quaternary ammonium group, Yis a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, Rand Rare independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.

The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions.

Cationic lipid vaccine compositions and methods of use

Compositions and methods for treating immune cells and activating immune responses are disclosed. The compositions comprise one or more optically active chiral cationic lipids.

Growing community of inventors

Bethel, CT, United States of America

Frank Bedu-Addo